tbuckley/cabot-search huggingface dataset:
224 M2 macrophage-mediated immune suppression of chimeric antigen receptor T cells via PD-L1 signaling in prostate cancer
Authors: Yukiko Yamaguchi, Jackson Gibson, Kevin Ou, Saul Priceman
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background The immune suppressive tumor microenvironment (TME) that inhibits T cell infiltration, survival, and anti-tumor activity has posed a major challenge for developing effective immunotherapies for solid tumors. Chimeric antigen receptor T cell therapy has shown unprecedented clinical response in treating patients with hematological malignancies, and intense investigation is underway to achieve similar responses with solid tumors. Immunologically cold tumors, including prostate cancers, are often infiltrated with abundant macrophages, and infiltration of M2 macrophages correlates with metastasis and poor prognosis. Methods To model this in vitro, we utilized a novel co-culture system with tumor cells, prostate stem cell antigen (PSCA)-directed CAR T cells, and polarized macrophages. To investigate the TME in vivo, we took advantage of ”humanized” MISTRG mice, which are immunocompromised mice with knocked-in human genes that support human hematopoiesis and efficient tumor-infiltration of myeloid cell populations. Humanized MISTRG mice were intratibially engrafted with LAPC9 tumor cells to model bone metastatic disease. Results We observed significant hampering of PSCA-CAR T cell activity in vitro with the presence of M2 macrophages, but not M1 macrophages, coinciding with a robust induction of PD-L1 in both tumor cells and macrophages. We also observed PD-L1 expression in tumor-associated macrophages infiltrating tumors following PSCA-CAR T cell therapy in the humanized mice. Anti-PD-L1 monoclonal antibodies in combination with CAR-T cell therapy altered phenotype and survival of M2 macrophages, resulting in improved anti-tumor activity of PSCA-CAR T cells in the presence of M2 macrophages. Conclusions Recently, immune checkpoint (IC) blockade (ICB) has been utilized in combination with chimeric antigen receptor (CAR) T cell therapy, with the notion that induction of immune responses with CAR T cells may instigate checkpoint pathways in immunologically cold tumors that would otherwise not respond to ICB. This study gives insights to a mechanism by which CAR T cells and ICB work in synergy to modulate immune landscape of immunologically cold tumors, and our ongoing studies will continue to elucidate the TME-mediated immunosuppression of CAR T cell therapy.
Obesity-Induced Inflammation Co-Operates with Clonal Hematopoiesis of Indeterminate Potential (CHIP) Mutants to Promote Leukemia Development and Cardiovascular Disease
Authors: Santhosh Kumar Pasupuleti, Baskar Ramdas, Sarah S. Burns, Ramesh Kumar, Taruni Reddy Pandhiri, George Sandusky, Zhi Yu, Michael Honigberg, Alexander G. Bick, Gabriel K. Griffin, Abhishek Niroula, Benjamin L. Ebert, Pradeep Natarajan, Reuben Kapur
Journal: Blood (2021)
CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC
Authors: Natasha B. Leighl, Scott A. Laurie, Glenwood D. Goss, Brett G.M. Hughes, Martin Stockler, Ming-Sound Tsao, David M. Hwang, Phillipe Joubert, Swati Kulkarni, Normand Blais, Anil A. Joy, Mihaela Mates, Punam Rana, Sunil K. Yadav, Craig Underhill, Christopher Lee, Penelope A. Bradbury, Andrea Hiltz, Janet Dancey, Keyue Ding, Francisco Vera-Badillo
Journal: Journal of Thoracic Oncology (2021)

First-line therapy for patients with metastatic NSCLC includes checkpoint inhibitor monotherapy, dual checkpoint inhibition, or combination with chemotherapy. We compared outcomes with combination chemoimmunotherapy versus dual checkpoint inhibition as first-line treatment for patients with metastatic NSCLC.This open-label, randomized clinical trial was conducted at 44 sites in Canada and Australia. Patients with treatment-naive, metastatic NSCLC without sensitizing EGFR or ALK alterations were randomized (1:1) to receive treatment with durvalumab plus tremelimumab with or without platinum-doublet chemotherapy. The primary end point was overall survival (OS). Secondary end points were progression-free survival, overall response rate, and safety.A total of 301 patients were randomized. Median OS was 16.6 months (95% confidence interval [CI]: 12.6-19.1) with chemotherapy plus immunotherapy and 14.1 months (95% CI: 10.6-18.3) with immunotherapy (hazard ratio = 0.88, 90% CI: 0.67-1.16, p = 0.46). Median progression-free survival with chemotherapy plus immunotherapy was 7.7 months (95% CI: 5.5-8.5) and 3.2 months (95% CI: 2.7-5.1) with immunotherapy (hazard ratio = 0.67, 95% CI: 0.52-0.88). The overall response rate with chemoimmunotherapy was 42.4% and 29.3% with immunotherapy (adjusted OR = 1.69, 95% CI: 1.04-2.76). The percentage of patients with grade 3 or higher adverse events was 82% in the chemotherapy plus immunotherapy group and 70% in the immunotherapy group. Exploratory analyses of programmed death-ligand 1 expression and blood-based tumor mutation burden revealed no differential treatment effect on OS.The addition of chemotherapy to durvalumab plus tremelimumab in the first-line treatment of stage IV NSCLC did not improve survival compared with durvalumab plus tremelimumab alone. Further study is warranted to identify patients that benefit from initial immunotherapy alone versus combination chemotherapy plus immunotherapy as first-line treatment.
Abstract 8984: Prediction of Functional Results of Percutaneous Coronary Interventions With Virtual Stenting and Quantitative Flow Ratio
Authors: Hyun-jong Lee, Mejía-Rentería Hernán, Javier Escaned, Joon-Hyung Doh, Joo Myung Lee, Doyeon Hwang, Sonoka Yuasa, Ki Hong Choi, Ho Jun Jang, KI-HYUN JEON, JUNEYOUNG LEE, Chang-Wook Nam, Eun-Seok Shin, Bon-Kwon Koo
Journal: Circulation (2021)

Introduction: The clinical value of residual quantitative flow ratio (rQFR), a novel function of QFR technique aimed to predict residual ischemia after virtual percutaneous coronary intervention (vPCI) is unknown. Hypothesis: We hypothesized rQFR well predict functional results after PCI. Methods: This is a sub-study of the COE-PERSPECTIVE registry, which investigated the prognostic value of post-PCI fractional flow reserve (FFR). From pre-PCI angiograms, QFR and rQFR were analyzed and their diagnostic performance was assessed at blinded fashion using pre-PCI FFR and post-PCI FFR as reference, respectively. The prognostic value of rQFR after vPCI was assessed according to vessel-oriented composite outcome (VOCO) (a composite of cardiac death, vessel-specific myocardial infarction, and vessel-specific revascularization) at 2 years. Results: Two hundred and seventy-four patients (274 vessels) with FFR-based ischemic causing lesions were analyzed. Pre-PCI QFR and FFR were 0.63±0.10 and 0.66±0.11 (R=0.756, p&lt;0.001). rQFR after vPCI and FFR after real PCI were 0.93±0.06 and 0.86±0.07 (R=0.528, p&lt;0.001). Diagnostic performance of rQFR to predict actual post-PCI FFR was good (area under the curve (AUC): 0.856 [0.804-0.909], p&lt;0.001). rQFR predicted well the incidence of 2-year VOCO after index PCI (AUC: 0.712 [0.555-0.869], p=0.041), being similar to that of actual post-PCI FFR (AUC: 0.691 [0.512-0.870], p=0.061). rQFR ≤0.89 was associated with increased risk of 2-year VOCO (hazard ratio: 12.9 [2.32-71.3], P=0.0035). Conclusions: Residual QFR estimated from pre-PCI angiography and virtual coronary stenting predicts procedural functional results and long-term vessel-related clinical events.
Fibrin(ogen) Promotes Immune Cell Infiltration, Dysbiosis and ROS Production in Experimental Colitis
Authors: Balkrishan Sharma, Ramesh Kudira, Leah A. Rosenfeldt, Benjamin E Gourley, Rachel Cantrell, Miki Watanabe, Olivia Edwards, Lindsey E Romick-Rosendale, David Haslam, Matthew J. Flick, Joseph S. Palumbo
Journal: Blood (2021)
A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Authors: Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Nikolaos Kanellias, Stavros Gkolfinopoulos, Kyriaki Manousou, Efstathios Kastritis, Meletios A. Dimopoulos
Journal: Blood (2021)
Distinct roles but cooperative effect of TLR3/9 agonists and PD-1 blockade in converting the immunotolerant microenvironment of irreversible electroporation-ablated tumors
Authors: Fatma Babikr, Jiangbo Wan, Aizhang Xu, Zhaojia Wu, Shahid Ahmed, Andrew Freywald, Rajni Chibbar, Yue Wu, Michael Moser, Gary Groot, Wenjun Zhang, Bing Zhang, Jim Xiang
Journal: Cellular and Molecular Immunology (2021)
Creating Clinical Meaning for the Promis Cognitive Function Abilities Instrument: Improving Remission Outcomes for Adults with Thrombotic Thrombocytopenic Purpura
Authors: Deirdra Terrell, Kalyn Neighbors, Amanda J Llaneza, Rachel Ann Kelley, Sara K. Vesely, Janna Journeycake, Mohamad O. Khawandanah, Marshall Mazepa, Frank Akwaa, Adam Cuker, Shruti Chaturvedi, Neil A. Zakai, Ming Yeong Lim, Radhika Gangaraju, San Keller, Spero Cataland
Journal: Blood (2021)
Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
Authors: Naveen K Yarlagadda, Meera Mohan, Shebli Atrash, Sravani Gundarlapalli, Shadiqul Hoque, Sunil Kakadia, Sharmilan Thanendrarajan, Carolina Schinke, Daisy Alapat, Guido Tricot, Erming Tian, Jeffery R. Sawyer, Fenghuang Zhan, Frits van Rhee, Maurizio Zangari
Journal: Blood (2021)
A Phase 1a/1b First in Human Study of PHI-101, a Potent Small Molecule Inhibitor of FLT3 in Relapsed and Refractory Acute Myeloid Leukemia
Authors: Sung-Soo Yoon, Dong-Yeop Shin, Je-Hwan Lee, Jun Ho Jang, June-Won Cheong, Ho-Jin Shin, Jeong-Ok Lee, Yunsuk Choi, Anish Puliyayil, Joseph Clarey, Jeejin Im, Ky-Youb Nam, Kyu-Tae Kim, June H-J. Han, Jeong-Hyeok Yoon, Bao Nguyen, Li Li, Donald Small
Journal: Blood (2021)
KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy
Authors: Adam J. Lamble, Regina M. Myers, Agne Taraseviciute, Samuel John, Bonnie Yates, Seth M. Steinberg, Jennifer Sheppard, Alexandra E. Kovach, Brent L. Wood, Michael Borowitz, Maryalice Stetler-Stevenson, Constance M. Yuan, Vinodh Pillai, Toni Foley, Perry Chung, Lee Chen, Daniel W. Lee, Colleen Annesley, Amanda M. DiNofia, Stephan A. Grupp, Michael R Verneris, Lia Gore, Theodore W. Laetsch, Deepa Bhojwani, Patrick A. Brown, Michael A. Pulsipher, Susan R. Rheingold, Rebecca A Gardner, Nirali N. Shah
Journal: Blood (2021)
Acute GvHD after HLA-Haploidentical Hematopoietic Cell Transplantation with Regulatory and Conventional T Cell Immunotherapy Does Not Adversely Affect Transplantation Outcomes
Authors: Samanta Bonato, Rachele Del Sordo, Antonella Mancusi, Adelmo Terenzi, Tiziana Zei, Roberta Iacucci Ostini, Sara Tricarico, Sara Piccinelli, Mario Griselli, Francesca Marzuttini, Valerio Viglione, Eleonora Torti, Rebecca Sembenico, Roberto Limongello, Mara Merluzzi, Eni Hoxha, Sara Ciardelli, Rosaria Sola, Franca Falzetti, Michele Giansanti, Massimo Fabrizio Martelli, Loredana Ruggeri, Alessandra Carotti, Andrea Velardi, Antonio Pierini
Journal: Blood (2021)
Deep Vein Thrombosis after COVID-19 Vaccinations
Authors: Damon E. Houghton, Anand Padmanabhan, Aneel A. Ashrani, Ewa Wysokinska, Rahul Chaudhary, Leslie Padrnos, Rajiv K. Pruthi, Meera Sridharan, Surbhi Shah, Waldemar E. Wysokinski
Journal: Blood (2021)
Characterization of LP-118, a Novel Small Molecule Inhibitor of Bcl-2 and Bcl-Xl in Chronic Lymphocytic Leukemia Resistant to Venetoclax
Authors: Janani Ravikrishnan, Elizabeth M. Muhowski, Tzung-Huei Lai, Shrilekha Misra, Daisy Diaz Rohena, Felai Tan, Yi Chen, Stephen P. Anthony, Yu Chen, Yue Shen, John C. Byrd, Deepa Sampath, Jennifer A. Woyach
Journal: Blood (2021)
New Approach to Decipher GATA2 Deficiency Syndrome: Focus on the Recurrent <i>GATA2</i> R396Q Mutation
Authors: Laetitia Largeaud, Laura Jamrog, Vincent Fregona, Camille Hamelle, Stephanie Dufrechou, Naïs Prade, Sylvie Hebrard, Esmaa Sellam, Manon Bayet, Christine Didier, Bastien Gerby, Eric Delabesse, Marlene Pasquet, Cyril Broccardo
Journal: Blood (2021)
Grappling with the granuloma: where is the ACE in the hole?
Authors: Andrew Bush, Rishi Pabary
Journal: Thorax (2021)

The finding of granulomas on paediatric tissue biopsy is non-specific, with a wide differential diagnosis that includes chronic infection (eg, tuberculous, atypical Mycobacterium infection, leprosy, Lyme disease, brucellosis, syphilis and histoplasmosis), immunodeficiency (hyper-IgM syndrome, chronic granulomatous disease), connective tissue disease (juvenile chronic arthritis) and miscellaneous conditions such as Blau’s syndrome, Melkersson-Rosenthal syndrome, Anderson-Fabry disease and Vogt-Koyanagi-Harada syndrome. Tumours such as hepatoblastoma and neuroblastoma may also provoke a granulomatous reaction.1 Another important differential is sarcoidosis which, like many of the above, is rare in children and has a wide clinical spectrum of severity. Older children with sarcoidosis usually have a presentation similar to adults, with frequent hilar lymphadenopathy and pulmonary infiltrates. Early-onset sarcoidosis, usually presenting before the age of four, is more frequently characterised by uveitis, rash and arthritis2 and one could question whether the two diseases are really the same entity.

Unlike some of the other conditions associated with granulomas, there is no specific diagnostic test for sarcoidosis. An elevated serum ACE is supportive but non-specific and there are cases diagnosed as sarcoidosis with no serum abnormality. Given that there is no gold-standard diagnosis test for sarcoidosis, and that sarcoidosis is likely an umbrella term under which lurk several different disease entities, how can we hope to make progress towards finding a specific cause, when the first prerequisite towards achieving this is to assemble a large cohort? Even …
The RNA m 6a Reader YTHDF2 Promotes Tumorigenesis of Diffuse Large B-Cell Lymphoma By Regulating ACER2-Ceramide Metabolic Axis
Authors: Xiangxiang Zhou, Xiaomin Chen, Yiqing Cai, Shunfeng Hu, Tiange Lu, Mengfei Ding, Xin Wang
Journal: Blood (2021)
Unleashing Cell-Intrinsic Inflammation As a Strategy to Kill AML Blasts
Authors: Jana M Ellegast, Gabriela Alexe, Amanda Hamze, Shan Lin, Maxim Pimkin, Linda Ross, Neekesh V Dharia, Amanda L Robinchaud, Amy Conway, Delan Khalid, Mark Wunderlich, Lina Benajiba, Behnam Nabet, Nathanael S Gray, Stuart H. Orkin, Kimberly Stegmaier
Journal: Blood (2021)
Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes
Authors: Monica Cusan, Karilyn Larkin, Deedra Nicolet, Vindi Jurinovic, Krzysztof Mrózek, Aarif M. N. Batcha, Maja Rothenberg-Thurley, Stephanie Schneider, Maria Cristina Sauerland, Dennis Görlich, Utz Krug, Wolfgang E. Berdel, Bernhard Josef Woermann, Wolfgang Hiddemann, Jan Braess, Karsten Spiekermann, Jessica Kohlschmidt, James S. Blachly, Alice S. Mims, Christopher J. Walker, Christopher C. Oakes, Shelley Orwick, Andrew J Carroll, William Blum, Bayard L. Powell, Jonathan E Kolitz, Joseph O. Moore, Robert James Mayer, Richard A. Larson, Richard M. Stone, John C. Byrd, Klaus H. Metzeler, Tobias Herold, Ann-Kathrin Eisfeld
Journal: Blood (2021)
Granuloma formation after peritoneal dialysis catheter–related infection by Mycobacterium chelonae
Authors: Ryunosuke Noda, Daisuke Kamano, Tatsuki Abe, Satoki Shinzawa, Manabu Takamatsu, Yuan Bae, Ryu Kobayashi, Mai Yanagi, Yoshitaka Ishibashi
Journal: Kidney International (2021)
<i>Selective Targeting of Immune Modulatory Proteins to Mitigate Fibrosis and Inflammation in Sclerodermatous Graft-Vs-Host Disease</i>
Authors: Lu Cui, Cristabelle De Souza, Tristan Lerbs, Jessica Poyser, Maryam Kooshesh, Atif Saleem, Kerri Rieger, Ryanne Brown, Bernice Kwong, Sebastian Fernandez-Pol, Sally Arai, Judith A Shizuru, Antonia MS Mueller, Gerlinde Wernig
Journal: Blood (2021)
N-Cadherin Stabilizes β-Catenin and Promotes β-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma
Authors: Shiqiao Ye, Yu Chen, Bo Hu, Huayu Huang, Yuxiao Sun, James P Stewart, Sarah K Johnson, Bart Barlogie, Maurizio Zangari, Guido Tricot, Faith E Davies, Gareth J Morgan, Brian A Walker, Fenghuang Zhan, Frits van Rhee, John D Shaughnessy, Ya-Wei Qiang
Journal: Blood (2021)
219 CD47 and phosphatidylserine contribute to the interaction between antigen presenting cells and the allogeneic cell-based relapse vaccine DCP-001
Authors: Haoxiao Zuo, Satwinder Kaur Singh, Marie-José Van Lierop, Jorn Kaspers, Remco Bos, Alwin Kamermans, Helga E de Vries, Tanja de Gruijl, Ada Kruisbeek, Erik Manting, Satwinder Kaur Singh
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background DCP-001 is a cancer relapse vaccine derived from the DCOne® human leukemic cell line. During manufacturing, DCOne® cells are shifted towards a mature dendritic cell (mDC) phenotype, combining an endogenous tumor antigen repertoire (e.g. WT-1, RHAMM and PRAME) with a mDC costimulatory profile and providing the basis for the highly immunogenic vaccine DCP-001. In a phase I clinical study in acute myeloid leukemia (AML), DCP-001 demonstrated to be safe and to induce multifunctional antitumor immune responses. 1 It has also been reported that DCP-001 induces antitumor immunity against multiple myeloma cells in peripheral blood mononuclear cells (PBMC) from multiple myeloma patients and that DCP-001 antigenic material is transferred to host antigen presenting cells (APC), possibly via extracellular vesicles. 2 However, the possibility of direct interactions between DCP-001 and host APC has not yet been investigated. Methods To further elucidate the mode of action of DCP-001, we studied the interactions of DCP-001 with human PBMC and isolated immature monocyte-derived DCs (iMoDC) in in vitro co-culture studies. A human skin explant model was used to determine uptake of DCP-001 by migrating skin DCs after intradermal injection. Results We found that DCP-001 stimulates the secretion of various proinflammatory cytokines (IL-1β, GM-CSF, IFN-γ, IL-2, TNF-α, and IL-6) and chemokines (IL-8 and RANTES) in PBMC. In addition, we demonstrate that DCP-001 is efficiently taken up by iMoDC via direct cell-cell interactions and that this phagocytic process is influenced by ”eat-me” and ”don’t eat me” signaling pathways. Blocking of the ”eat-me” signals calreticulin and phosphatidylserine inhibited the uptake of DCP-001, whereas blockade of the ”don’t eat me” signal CD47 enhanced DCP-001 uptake. After intradermal injection of DCP-001 in an ex-vivo human skin model, its uptake by skin-emigrating DCs was demonstrated as well as simultaneous activation of these DCs. Conclusions Our data suggest a key role for host antigen presenting cells in the triggering of immune responses upon DCP-001 vaccination. In addition, the data provide rationale for potential combination therapies based on DCP-001 and inhibitors of the CD47 pathway. References van de Loosdrecht AA, et al . A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia. Cancer Immunol Immunother 2018; 67 (10):1505–1518. Leaf RK, et al . DCOne as an allogeneic cell-based vaccine for multiple myeloma. J Immunother 2017; 40 (9):315–322.
Access to CAR-T Cell Therapy in Underrepresented Populations: A Multicenter Cohort Study of Pediatric and Young Adult ALL Patients
Authors: Anurekha G. Hall, Lena E. Winestone, Erin M. Sullivan, Qian Vicky Wu, Adam J. Lamble, Mark C. Walters, Paibel Aguayo-Hiraldo, Lourdes Baez Conde, Tumaini R. Coker, Hema Dave, Dana Dornsife, Amy K. Keating, Diana M. Merino, Bonnie Ramsey, Julie R. Park, Anurag K. Agrawal
Journal: Blood (2021)
Embedding planetary health into health authority guidelines
Authors: Nicolas Faure
Journal: BMJ (2021)

Moore calls for a planetary health curriculum.1 Tackling climate change and biodiversity loss is vital because of their catastrophic health consequences. To limit global temperature rise below 1.5°C, we must cut greenhouse gas emissions and advocate for wide and equitable changes in societies.2

The World Organization of Family Doctors (WONCA) is currently providing GPs with knowledge and …
12-Month Analysis of a Phase 2 Study of Iptacopan (LNP023) Monotherapy for Paroxysmal Nocturnal Hemoglobinuria
Authors: Jun-Ho Jang, Lily LL Wong, Bor-Sheng Ko, Sung-Soo Yoon, Katie Li, Izabela Rozenberg, Prasanna K Nidamarthy, Raghav Chawla, Guido Junge, Eng Soo Yap
Journal: Blood (2021)
Assessment of an Embedded Primary Care-Derived Electronic Health Record Frailty Index (eFI) in Older Adults with Acute Myeloid Leukemia
Authors: Justin J. Cheng, Janet A. Tooze, Kathryn E. Callahan, Nicholas M. Pajewski, Timothy S. Pardee, Daniel R. Reed, Heidi D. Klepin
Journal: Blood (2021)
Encouraging Survival and High Rates of Toxicity: Allogeneic Hematopoietic Cell Transplantation after Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Aggressive Lymphoma Patients
Authors: Shalev Fried, Ivetta Danylesko, Ronit Yerushalmi, Noga Shem-Tov, Roni Shouval, Joshua A Fein, Zachary Cohen, Elad Jacoby, Michal Besser, Arnon Nagler, Avichai Shimoni, Abraham Avigdor
Journal: Blood (2021)
Non-Relapse Mortality in <i>TP53</i>-Mutated MDS/AML - a Multi-Center Collaborative Study
Authors: Michael T. Byrne, Tony J Kurian, Dilan A Patel, Roni Tamari, Sanghee Hong, Haitham Abdelhakim, Victoria Klein, Patricio Rojas, Raksha Madhavan, Andrew Kent, Aaron C. Logan, Catherine J. Lee, Muhammad Husnain, Benjamin M Manning, Nicholas P. Tschernia, Ajoy L. Dias, Daniel Margalski, Benjamin Goldenson, Nathalie Byrne, Heidi Chen, Kseniya Petrova-Drus, Salyka M. Sengsayadeth, Aaron M Goodman, Dianna S. Howard, William A. Wood, Saar Gill, Antonio M. Jimenez, Jonathan A. Gutman, Lohith Gowda, Leland Metheny, Bhavana Bhatnagar, Betty K. Hamilton, Asmita Mishra, Michael R. Savona
Journal: Blood (2021)